A Phase 3 interventional study of Therapy and Midomafetamine in Posttraumatic Stress Disorder, sponsored by Lykos Therapeutics. Completed at 14 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-06.
Sponsored by Lykos Therapeutics (part of Resilient Pharmaceuticals) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic — 11 open to participants now, 12 under way, 1 of them phase 3. N-Methyl-3,4-methylenedioxyamphetamine · Stress Disorders, Post-Traumatic.
Among the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, this one is the 3rd largest by enrollment, is one of 2 that started in 2020, is one of 6 in phase 3, and was the 16th registered.
2,688 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 606 are open to participants now.
Browse Stress Disorders, Post-Traumatic studies →11 of the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic are open now, in 3 countries. Recruiting first, the newest first:
Emory University · Sites in United States
Ages 21–70
Sunstone Medical · Sites in United States
Ages 18+
Sheba Medical Center · Sites in Israel
Ages 18–75
Johns Hopkins University · Sites in United States
Ages 21+
Bronx VA Medical Center · Sites in United States
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 30 · Phase 3 6
First in 2004; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 121 is above the median of 69 across 2,202 interventional studies indexed under Stress Disorders, Post-Traumatic.
Median enrollment 25 across the 38 interventional studies. Of the 22 that completed or were terminated, 16 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 38 have an industry lead sponsor. The 10 most frequent:
This study is registered under Lykos Therapeutics, one of the names counted as Resilient Pharmaceuticals. Under that name alone:
Lykos Therapeutics is the lead sponsor of 28 studies on the registry; 1 is open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
20 studies in Stress Disorders, Post-Traumatic by Resilient Pharmaceuticals: none open now, none under way, none of them phase 3. Of 17 finished, 15 (88%) have results posted.
Among the 20 studies in Stress Disorders, Post-Traumatic by Resilient Pharmaceuticals, this one has the largest enrollment of the 17 interventional ones that give a count, is the only one that started in 2020, is one of 3 in phase 3, and was the 14th registered.
Resilient Pharmaceuticals’s Stress Disorders, Post-Traumatic studies by the year they started, since 2004.
4 of the studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06117306Phase 3Healing BreakthroughMDMA-assisted Massed Prolonged Exposure for PTSD | 2027-03 |
| NCT07569159Sunstone MedicalMDMA Therapy in Veterans With PTSD | 2027-04-01 |
| NCT05837845Patricia SuppesMDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder | 2027-05 |
| NCT05732155Guy SchusheimPreliminary Effectiveness of Hybrid Individual and Group MDMA-assisted Therapy for War-related PTSD | 2027-06-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Resilient Pharmaceuticals’s 20 in Stress Disorders, Post-Traumatic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people with at least moderate PTSD.
The main question it aims to answer is: Do three sessions of MDMA-assisted therapy reduce PTSD symptoms?
Researchers will compare three sessions of MDMA-assisted therapy with an initial dose of 80 to 120 mg to three sessions of placebo with therapy.
Participants will undergo three preparatory sessions without any study drug, followed by three MDMA-assisted therapy or placebo with therapy sessions. Each medication session will be followed by three integrative therapy sessions without study drug.
This multi-site, double-blind, placebo-controlled, randomized Phase 3 study will assess the efficacy and safety of MDMA-assisted psychotherapy versus psychotherapy with placebo control in participants diagnosed with at least moderate PTSD. The study will be conducted in N ≈ 100 participants. Participants will be randomized into one of two groups (MDMA or placebo) in a 1:1 ratio. An initial dose of MDMA or placebo, followed by a supplemental half-dose unless contraindicated, will be administered during the Treatment Period with manualized psychotherapy in three monthly Experimental Sessions. This \~12-week Treatment Period is preceded by three Preparatory Sessions. Initial doses per Experimental Session include 80 mg or 120 mg of midomafetamine HCl or placebo followed 1.5 to 2 hours later by a supplemental half-dose (40 or 60 mg). Total amounts of midomafetamine HCl to be administered per Experimental Session range from 80 mg to 180 mg. Each Experimental Session will be followed by three Integrative Sessions of non-drug psychotherapy to help the participants process and understand their experiences during the Experimental Sessions.
The primary objective of this study is to evaluate the efficacy of MDMA-assisted psychotherapy for PTSD compared to identical psychotherapy with inactive placebo, as measured by change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total Severity Score from Visit 3 (Baseline) to Visit 19 (18 weeks post Baseline) (Blake et al., 1995). The key secondary objective of this study is to evaluate the efficacy of MDMA-assisted psychotherapy for PTSD compared to identical psychotherapy with inactive placebo in clinician-rated functional impairment, as measured by the change in Sheehan Disability Scale (adapted SDS) item scores from Visit 3 (Baseline) to Visit 19 (18 weeks post Baseline) (Leon et al., 1997).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administration of 80 to 120 mg midomafetamine HCl in combination with manualized psychotherapy, followed by a supplemental half-dose 1.5 to 2 hrs after the initial dose of 40 or 60 mg, respectively.
Behavioral: Therapy · Drug: Midomafetamine
Administration of inactive placebo in combination with manualized psychotherapy.
Behavioral: Therapy · Drug: Placebo
Standardized non-directive therapy performed by therapist team.
Also known as: Manualized MDMA-assisted therapy
Administration of 80 to 120 mg midomafetamine HCl, followed by a supplemental half-dose 1.5 to 2 hrs after the initial dose of 40 or 60 mg, respectively, during three sessions of MDMA-assisted psychotherapy.
Also known as: 3,4-methylenedioxymethamphetamine, MDMA
Administration of placebo with therapy during three experimental sessions
Also known as: Inactive placebo
Change From Baseline to Primary Endpoint in Clinician Administered PTSD Scale for DSM-V (CAPS-5)
The CAPS-5 is a 30-item semi-structured interview assessing PTSD in the past month through diagnostic and symptom severity scores anchored to a DSM-5 defined traumatic event. The CAPS-5 produces a Total Severity Score based on severity of PTSD domains described in the DSM-5, as well as a categorical rating indicating whether a participant meets PTSD diagnostic criteria. CAPS-5 Total Symptom Severity scores range from 0 to 80 with higher values indicating greater symptom severity. CAPS-5 assigns PTSD diagnosis as being present or absent.
Time frame: Baseline to 18 weeks post baseline post enrollment confirmation
Change From Baseline to Primary Endpoint in Adapted Sheehan Disability Scale (SDS) Total Score
The Sheehan Disability Scale (SDS) is a clinician-rated assessment of functional impairment that was adapted for the purposes of this study to limit missing item-level data as per the FDA requirements and included use of the three-item mean as the total score and imputation of work-related impairment. The SDS is a 3-item scale measuring the severity of disability in the domains of work, family life/home responsibilities and social/leisure activities, with each item scored on a ten-point Likert scale from 0 ('not at all impaired') to 10 ('very severely impaired'). The SDS total score was the mean of the 3 item responses. The SDS total score ranged from 0 to 10, with higher scores indicating greater functional impairment.
Time frame: Baseline to 18 weeks post enrollment confirmation
Participants were recruited through print and internet advertisements, referrals from other treatment providers, and by word of mouth.
| Milestone | Experimental: MDMA-assisted Psychotherapy | Placebo Comparator: Placebo With Psychotherapy |
|---|---|---|
| Started | 53 | 51 |
| Completed | 52 | 42 |
| Not completed | 1 | 9 |
The CAPS-5 is a 30-item semi-structured interview assessing PTSD in the past month through diagnostic and symptom severity scores anchored to a DSM-5 defined traumatic event. The CAPS-5 produces a Total Severity Score based on severity of PTSD domains described in the DSM-5, as well as a categorical rating indicating whether a participant meets PTSD diagnostic criteria. CAPS-5 Total Symptom Severity scores range from 0 to 80 with higher values indicating greater symptom severity. CAPS-5 assigns PTSD diagnosis as being present or absent.
| score on a scale | Experimental: MDMA-assisted Psychotherapy | Placebo Comparator: Placebo With Psychotherapy |
|---|---|---|
| Change From Baseline to Primary Endpoint in Clinician Administered PTSD Scale for DSM-V (CAPS-5) | -23.69 (-26.94 to -20.44) | -14.78 (-18.28 to -11.28) |
The Sheehan Disability Scale (SDS) is a clinician-rated assessment of functional impairment that was adapted for the purposes of this study to limit missing item-level data as per the FDA requirements and included use of the three-item mean as the total score and imputation of work-related impairment. The SDS is a 3-item scale measuring the severity of disability in the domains of work, family life/home responsibilities and social/leisure activities, with each item scored on a ten-point Likert scale from 0 ('not at all impaired') to 10 ('very severely impaired'). The SDS total score was the mean of the 3 item responses. The SDS total score ranged from 0 to 10, with higher scores indicating greater functional impairment.
| score on a scale | Experimental: MDMA-assisted Psychotherapy | Placebo Comparator: Placebo |
|---|---|---|
| Change From Baseline to Primary Endpoint in Adapted Sheehan Disability Scale (SDS) Total Score | -3.31 (-4.03 to -2.60) | -2.11 (-2.89 to -1.33) |
Collected over During the Treatment Period from the first Experimental Session to the last Integrative Session (approximately 12 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MDMA-assisted Therapy | 0/53 (0%) | 0/53 (0%) | 53/53 (100%) |
| Placebo With Therapy | 0/51 (0%) | 0/51 (0%) | 49/51 (96.1%) |
| Event | MDMA-assisted Therapy | Placebo With Therapy |
|---|---|---|
| HeadacheNervous system disorders | 38/53 | 31/51 |
| Muscle tightnessMusculoskeletal and connective tissue disorders | 31/53 | 13/51 |
| NauseaGastrointestinal disorders | 24/53 | 11/51 |
| Suicidal ideationPsychiatric disorders | 18/53 | 21/51 |
| Decreased appetiteMetabolism and nutrition disorders | 19/53 | 5/51 |
| InsomniaPsychiatric disorders | 19/53 | 15/51 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 18/53 | 3/51 |
| DizzinessNervous system disorders | 15/53 | 8/51 |
| AnxietyPsychiatric disorders | 15/53 | 12/51 |
| FatigueGeneral disorders | 14/53 | 9/51 |
| Age, Continuous(years) | Experimental: MDMA-assisted Psychotherapy | Placebo Comparator: Placebo With Psychotherapy | Total |
|---|---|---|---|
| Mean | 38.2 ± 11.0 | 39.9 ± 9.6 | 39.1 ± 10.3 |
| Sex: Female, Male(Participants) | Experimental: MDMA-assisted Psychotherapy | Placebo Comparator: Placebo With Psychotherapy | Total |
|---|---|---|---|
| Female | 32 | 42 | 74 |
| Male | 21 | 9 | 30 |
| Ethnicity (NIH/OMB)(Participants) | Experimental: MDMA-assisted Psychotherapy | Placebo Comparator: Placebo With Psychotherapy | Total |
|---|---|---|---|
| Hispanic or Latino | 17 | 11 | 28 |
| Not Hispanic or Latino | 36 | 39 | 75 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Experimental: MDMA-assisted Psychotherapy | Placebo Comparator: Placebo With Psychotherapy | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 2 | 2 |
| Asian | 5 | 6 | 11 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 5 | 3 | 8 |
| White | 37 | 32 | 69 |
| More than one race | 6 | 7 | 13 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Baseline PTSD Duration(years) | Experimental: MDMA-assisted Psychotherapy | Placebo Comparator: Placebo With Psychotherapy | Total |
|---|---|---|---|
| Mean | 16.3 ± 14.3 | 16.1 ± 12.4 | 16.2 ± 13.3 |
| Baseline CAPS-5 Dissociative Subtype(Participants) | Experimental: MDMA-assisted Psychotherapy | Placebo Comparator: Placebo With Psychotherapy | Total |
|---|---|---|---|
| Count of participants | 13 | 11 | 24 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — We will share outcome data appearing in any published reports upon request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data and study-related documents will be available when the database has been locked and data has been unblinded.
Access criteria: Interested persons should correspond with the central contact for the multisite study.
Ran from Sep 2020 to primary completion in Oct 2022, 25 months.
Results were first posted in Oct 2023, 11 months after primary completion.
Of 34 phase 3 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's 25 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: N-Methyl-3,4-methylenedioxyamphetamine
Stress Disorders, Post-Traumatic →